In this study, we assessed the prevalence of KRAS genetic alterations, including point mutations, copy number alterations, and gene fusion in both the primary tumors (TCGA) and metastatic tumor samples (MSKCC-IMPACT) at the Pan-Cancer scale. This evidence concerns the gene KRAS and cancer.